Kynam Capital Management, LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Kynam Capital Management, LP reported 29 stock positions worth $1.5 billion. Its top holding was Natera (NTRA) at 21.1% of the portfolio, followed by Vaxcyte (PCVX, 12.6%) and Celldex Therapeutics (CLDX, 8.4%). Compared with Q3 2024, it opened 5 new positions, added to 13 and reduced 5. The biggest buy was Vaxcyte (PCVX, shares +125%) and the biggest sale Cogent Biosciences (COGT, shares −1%).
- Most Recent 13F
- Q2 2026
- Location
- PRINCETON, NJ
- CIK
- 0001907884
- Portfolio Value
- $1.5B (Q4 2024)
- SEC Filing
- 0001085146-25-001501 ↗ filed Feb 14, 2025
Holdings Value
Holdings 29 stocks · $1.5B
| NTRA Natera Inc. | 21.11% | 2,022,098 | $320.1M | Reduce -1.0% |
| PCVX Vaxcyte Inc. | 12.62% | 2,336,796 | $191.3M | Add +124.8% |
| CLDX Celldex Therapeutics Inc. | 8.44% | 5,064,207 | $128.0M | Add +46.4% |
| SNDX Syndax Pharmaceuticals Inc. | 7.43% | 8,520,000 | $112.6M | Add +45.8% |
| DVAX Dynavax Technologies Corp. | 5.53% | 6,560,835 | $83.8M | Reduce -21.3% |
| CGON CG Oncology Inc. | 4.77% | 2,519,705 | $72.3M | Add +42.3% |
| COGT Cogent Biosciences Inc. | 4.68% | 9,105,000 | $71.0M | Reduce -1.5% |
| BCRX Biocryst Pharmaceuticals Inc. | 4.51% | 9,085,368 | $68.3M | No change |
| VRDN Viridian Therapeutics Inc. | 4.21% | 3,326,262 | $63.8M | Add +32.5% |
| VERA Vera Therapeutics Inc. | 4.07% | 1,457,910 | $61.7M | Reduce -7.5% |
| WVE Wave Life Sciences Ltd. | 4.00% | 4,899,497 | $60.6M | No change |
| BEAM Beam Therapeutics Inc. | 2.87% | 1,756,158 | $43.6M | Add +34.9% |
| IMCR Immunocore Holdings PLC-ADR | 2.38% | 1,225,576 | $36.2M | New |
| ENGN Engene Holdings Inc. | 2.19% | 4,994,090 | $33.2M | Add +187.6% |
| TVTX Travere Therapeutics Inc. | 2.07% | 1,802,750 | $31.4M | Add +31.4% |
| LQDA Liquidia Corp. | 1.76% | 2,266,328 | $26.7M | No change |
| IRWD Ironwood Pharmaceuticals Inc. | 1.37% | 4,685,563 | $20.8M | Add +27.1% |
| TSVT 2SEVENTY Bio Inc. | 1.15% | 5,953,825 | $17.5M | No change |
| CGEM Cullinan Therapeutics Inc. | 1.01% | 1,252,738 | $15.3M | New |
| PTGX Protagonist Therapeutics Inc. | 0.99% | 390,792 | $15.1M | Reduce -14.4% |
| TYRA Tyra Biosciences Inc. | 0.49% | 530,478 | $7.4M | Add +13.4% |
| BNR Burning Rock Biotech Ltd.-ADR | 0.44% | 994,883 | $6.7M | Add +0.6% |
| STRO Sutro Biopharma Inc. Com SHS | 0.44% | 3,641,447 | $6.7M | Add +76.2% |
| AMARIN CORP PLC | 0.40% | 12,414,628 | $6.0M | No change |
| PRQR Proqr Therapeutics NV | 0.31% | 1,750,000 | $4.6M | New |
| RLAY Relay Therapeutics Inc. | 0.27% | 1,000,000 | $4.1M | New |
| CRBU Caribou Biosciences Inc. | 0.25% | 2,406,147 | $3.8M | Add +2.1% |
| SLRN Acelyrin Inc. | 0.18% | 847,366 | $2.7M | No change |
| CLYM Climb Bio Inc. | 0.06% | 547,000 | $985K | New |
Options reported separately and not counted above: SPY puts ($175.8M).
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
| PCVX Vaxcyte Inc. | Add +124.8% | 12.62% | +3.42 |
| IMCR Immunocore Holdings PLC-ADR | New | 2.38% | +2.38 |
| ENGN Engene Holdings Inc. | Add +187.6% | 2.19% | +1.30 |
| CGEM Cullinan Therapeutics Inc. | New | 1.01% | +1.01 |
| TVTX Travere Therapeutics Inc. | Add +31.4% | 2.07% | +0.58 |
| BEAM Beam Therapeutics Inc. | Add +34.9% | 2.87% | +0.40 |
| PRQR Proqr Therapeutics NV | New | 0.31% | +0.31 |
| RLAY Relay Therapeutics Inc. | New | 0.27% | +0.27 |
| BNR Burning Rock Biotech Ltd.-ADR | Add +0.6% | 0.44% | +0.19 |
| IRWD Ironwood Pharmaceuticals Inc. | Add +27.1% | 1.37% | +0.19 |
| CLYM Climb Bio Inc. | New | 0.06% | +0.06 |
| CRBU Caribou Biosciences Inc. | Add +2.1% | 0.25% | −0.11 |
| STRO Sutro Biopharma Inc. Com SHS | Add +76.2% | 0.44% | −0.11 |
| VRDN Viridian Therapeutics Inc. | Add +32.5% | 4.21% | −0.22 |
| TYRA Tyra Biosciences Inc. | Add +13.4% | 0.49% | −0.37 |
| CGON CG Oncology Inc. | Add +42.3% | 4.77% | −0.41 |
| CLDX Celldex Therapeutics Inc. | Add +46.4% | 8.44% | −0.67 |
| SNDX Syndax Pharmaceuticals Inc. | Add +45.8% | 7.43% | −1.29 |
Options Activity Q3 2024 → Q4 2024
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 300,000 | $175.8M |
| VRTX Vertex Pharmaceuticals Inc. | put | Sold out | 30,000 | $14.0Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $1.8B | CLDX, SNDX, PCVX, COGT, VERA |
| Q1 2026 | 36 | $1.6B | SNDX, CLDX, PCVX, COGT, VERA |
| Q4 2025 | 35 | $1.5B | COGT, VERA, SNDX, CLDX, PCVX |
| Q3 2025 | 35 | $1.3B | CLDX, SNDX, VERA, COGT, PCVX |
| Q2 2025 | 31 | $928.8M | CLDX, PCVX, VERA, SNDX, BCRX |
| Q1 2025 | 31 | $1.2B | NTRA, PCVX, CLDX, SNDX, BCRX |
| Q4 2024 | 29 | $1.5B | NTRA, PCVX, CLDX, SNDX, DVAX |
| Q3 2024 | 24 | $1.3B | NTRA, PCVX, CLDX, SNDX, COGT |
| Q2 2024 | 22 | $955.2M | NTRA, CLDX, SNDX, DVAX, COGT |
| Q1 2024 | 21 | $898.9M | NTRA, SNDX, CLDX, VERA, COGT |